Andoh-Noda Tomoko, Inouye Michiko O, Miyake Kunio, Kubota Takeo, Okano Hideyuki, Akamatsu Wado
Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
CNS Neurol Disord Drug Targets. 2016;15(5):544-50. doi: 10.2174/1871527315666160413120156.
Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.
瑞特综合征(RTT)是一组神经发育障碍疾病之一,其典型特征是X连锁基因MECP2(甲基CpG结合蛋白2)存在缺陷。MECP2基因编码一种多功能蛋白,参与转录抑制、转录激活、染色质重塑和RNA剪接。在小鼠中基因敲除Mecp2会导致包括类似RTT表型在内的神经元功能障碍,并为理解RTT的发病机制提供了一个极佳的平台。到目前为止,由于对MECP2在RTT中的作用尚未完全了解,因此尚无针对RTT的有效药物治疗方法。最近,人类诱导多能干细胞(hiPSC)技术增进了我们对包括RTT在内的神经和神经发育疾病的认识,因为源自RTT-hiPSC的神经元可用于疾病建模,以了解RTT表型并进行高通量药物筛选。在本综述中,我们概述了RTT,包括MeCP2功能和RTT的小鼠模型。此外,我们介绍了使用hiPSC衍生的神经细胞进行RTT疾病建模的最新进展。